Trials / Unknown
UnknownNCT05045937
Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Patrick Robinson · Academic / Other
- Sex
- All
- Age
- 12 Years – 110 Years
- Healthy volunteers
- Accepted
Summary
Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery.
Detailed description
Patients at local physician clinics as well as my own clinic will be enrolled at the time they are evaluated for having COVID-19. Patients enrollment will be voluntary and based upon their request for treatment with Ivermectin. These patients will be questioned on symptoms and the timing of those symptoms in detail. They will then be followed throughout their treatment course to evaluate their recovery experience. Detailed accounts of their symptoms and their resolution will be followed. The study patients will stop being followed when they are either admitted to the hospital or are deemed to be symptom free. Any other medications prescribed to the patients will also be tracked. Medical histories will be taken and documented to make comparisons at the end of the study. Those patients not requesting Ivermectin will also be followed for comparisons at a later date.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivermectin | Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach. |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2021-09-16
- Last updated
- 2022-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05045937. Inclusion in this directory is not an endorsement.